- Unicycive gets second CRL for kidney drug as manufacturing woes continueUnicycive Therapeutics’ chronic kidney disease drug was rejected by the FDA for a second time over persistent issues at a third-party contract manufacturer. The company’s phosphate binder drug ox…Endpoints · 24d ago↗ source
- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseSanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking…Endpoints · 24d ago↗ source
- Beeline adds $126M to Bain-backed immunology pipeline from Bristol MyersBristol Myers Squibb spinout Beeline Medicines is getting extra love from its existing backers and some of its management team. Bain Capital, the Canada Pension Plan Investment Board, and Bristol…